BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 20845250)

  • 1. [Anti-VEGF inhibitors and their role in the treatment of diabetic macular oedema].
    Kakkassery V; Winterhalter S; Joussen AM
    Klin Monbl Augenheilkd; 2010 Sep; 227(9):701-11. PubMed ID: 20845250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology.
    Ho AC; Scott IU; Kim SJ; Brown GC; Brown MM; Ip MS; Recchia FM
    Ophthalmology; 2012 Oct; 119(10):2179-88. PubMed ID: 22917890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
    Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
    Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-vascular endothelial growth factor drug treatment of diabetic macular edema: the evolution continues.
    Stewart MW
    Curr Diabetes Rev; 2012 Jul; 8(4):237-46. PubMed ID: 22515701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetic macular edema.
    Lang GE
    Ophthalmologica; 2012; 227 Suppl 1():21-9. PubMed ID: 22517122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [From scientific evidence to clinical practice: treatment protocols for diabetic macular edema].
    López-Gálvez MI; García-Campos JM
    Arch Soc Esp Oftalmol; 2012 Dec; 87 Suppl 1():38-45. PubMed ID: 24278988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for anti-VEGF treatment of diabetic macular edema.
    Bandello F; Berchicci L; La Spina C; Battaglia Parodi M; Iacono P
    Ophthalmic Res; 2012; 48 Suppl 1():16-20. PubMed ID: 22907145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.
    Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS
    Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-VEGF therapeutic approaches for diabetic macular edema.
    Khurana RN; Do DV; Nguyen QD
    Int Ophthalmol Clin; 2009; 49(2):109-19. PubMed ID: 19349791
    [No Abstract]   [Full Text] [Related]  

  • 10. Current intravitreal pharmacologic therapies for diabetic macular edema.
    Colucciello M
    Postgrad Med; 2015 Aug; 127(6):640-53. PubMed ID: 26036708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of anti-growth factor therapies for diabetic macular edema: summary of primary findings and conclusions.
    O'Malley PG
    Arch Intern Med; 2012 Jul; 172(13):1014-5. PubMed ID: 22688778
    [No Abstract]   [Full Text] [Related]  

  • 12. Vascular Endothelial Growth Factor and Diabetic Retinal Disease.
    Ajlan RS; Silva PS; Sun JK
    Semin Ophthalmol; 2016; 31(1-2):40-8. PubMed ID: 26959128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic Safety of Prolonged Monthly Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema: A Systematic Review and Meta-analysis.
    Avery RL; Gordon GM
    JAMA Ophthalmol; 2016 Jan; 134(1):21-9. PubMed ID: 26513684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diabetic maculopathy. Diagnosis and treatment].
    Gelisken F; Ziemssen F
    Ophthalmologe; 2010 Aug; 107(8):773-86; quiz 787-8. PubMed ID: 20658139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-vascular endothelial growth factor agents for diabetic maculopathy.
    Salam A; DaCosta J; Sivaprasad S
    Br J Ophthalmol; 2010 Jul; 94(7):821-6. PubMed ID: 19556214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
    Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective and pan-blockade agents in the anti-angiogenic treatment of proliferative diabetic retinopathy: a literature summary.
    Giuliari GP; Guel DA; Cortez MA; Cortez RT
    Can J Ophthalmol; 2010 Oct; 45(5):501-8. PubMed ID: 20648074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-VEGF Molecules for the Management of Diabetic Macular Edema.
    Bandello F; Cicinelli MV; Parodi MB
    Curr Pharm Des; 2015; 21(32):4731-7. PubMed ID: 26350530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal anti-VEGF drugs as adjuvant therapy in diabetic retinopathy surgery.
    Montero JA; Ruiz-Moreno JM; Correa ME
    Curr Diabetes Rev; 2011 May; 7(3):176-84. PubMed ID: 21438852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
    Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
    JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.